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We aimed to evaluate the risk of atrial fibrillation (AF) development following retinal vein occlusion 
(RVO). We performed a nationwide propensity score-matched cohort study by retrospectively reviewing 
a database from the Korean National Health Insurance Service, comprising approximately 1 million 
random subjects. RVO and AF were diagnosed based on the Korean Classification of Disease codes. 
The RVO group was composed of patients with an initial diagnosis of RVO made between 2003 and 
2007 (n = 1,801), excluding those who were diagnosed in 2002. The comparison group was composed 
of randomly selected patients (5 for each patient with RVO, n = 8,930) who were matched to the RVO 
group according to sociodemographic factors and the year of enrollment. Each sampled patient was 
tracked until 2013. The predictive value of RVO for AF was analyzed using Cox regression analysis with 
a hazard ratio (HR) and confidence interval (CI). AF developed in 6.5% of patients in the RVO group 
and 4.0% of those in the comparison group (p < 0.001). RVO was associated with a greater risk of AF 
development after adjusting for possible confounders (HR, 1.35; 95% CI, 1.09–1.67). An association 
between RVO and subsequent AF development was found after adjusting for possible confounding 
factors.
If the central retinal vein or one of its main four branches is occluded, retinal hemorrhage and retinal edema 
subsequently occur and frequently cause low vision or blindness in adults1. This is called retinal vein occlusion 
(RVO), and there are two types: branch RVO (BRVO) and central RVO (CRVO). The suggested mechanisms of 
CRVO are increasing intraocular pressure, an atherosclerotic central retinal artery, and deformation of the lam-
ina. For BRVO, the suggested mechanisms are interrupted venous flow at the arteriovenous crossing by arterial 
stiffening due to atherosclerosis2. Several previous studies have shown that RVO increases the risk of cardiovas-
cular/cerebrovascular disease and their associated mortalities3–14. Considering the data for the risks of subsequent 
stroke or myocardial infarction following RVO development, it seems likely that small-sized to medium-sized 
vascular disease of the eye is associated with a higher likelihood of cardiovascular disease.
Atrial fibrillation (AF) is common in the elderly, and it is a significant public health problem associated with 
increased mortality and high cardiovascular morbidities such as stroke and heart failure (HF)15. In the United 
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States, AF is predicted to affect 6–12 million people by 2050 because of the aging population16. To the best of our 
knowledge, the association between RVO and AF has not been established previously in a longitudinal study 
with a large sample size. Therefore, in the current study, we investigated the risk of subsequent AF development 
following RVO using a representative nationwide sample of 1 million participants, which was provided by the 
National Health Insurance Service -National Sample Cohort from 2002–2013 (NHIS-NSC 2002–2013) database 
in South Korea.
Results
Patients’ baseline characteristics. Overall, 10,731 subjects, including 1,801 patients with RVO and 8,930 
controls, were eligible for analysis (Table 1). During the entire study period (median, 7.7 years), AF occurred 
more frequently in subjects with RVO than in those without RVO (6.5% vs. 4.0%, p < 0.001). Comorbidities 
including HF, cerebrovascular disease, hypertension, diabetes mellitus (DM), chronic kidney disease (CKD), and 
liver disease were more common in the RVO group than in the sociodemographic-matched comparison group 
(p < 0.001, all). For sociodemographic variables, we found no difference in the proportion of patients according 
to the presence of RVO, which was used to perform matching between the two groups.
Variables
Comparison group  
(column %)
RVO group  
(column %) P value
Atrial fibrillation < 0.001
 No 8,577 (96.1) 1684 (93.5)
 Yes 353 (4.0) 117 (6.5)
Co-morbidities
 Heart failure 2,157 (24.2) 633 (35.2) < 0.001
 Hyperthyroidism 115 (1.3) 31 (1.7) 0.147
 Acute Myocardial Infarction 124 (1.4) 32 (1.8) 0.209
 Cerebrovascular disease 815 (9.1) 245 (13.6) < 0.001
 Hypertension 3,499 (39.2) 1082 (60.1) < 0.001
 Diabetes mellitus 1,686 (18.9) 534 (29.7) < 0.001
 Chronic kidney disease 251 (2.8) 111 (6.2) < 0.001
 Chronic lung disease 2,651 (29.7) 574 (31.9) 0.065
 Liver disease 1,526 (17.1) 406 (22.5) < 0.001
Variables for matching
 Year
  2003 1,786 (20.0) 362 (20.1) 0.991
  2004 1,972 (22.1) 396 (22.0)
  2005 1,666 (18.7) 328 (18.2)
  2006 1,622 (18.2) 328 (18.2)
  2007 1,884 (21.1) 387 (21.5)
 Age group (year) 0.998
  < 50 1,841 (20.6) 370 (20.5)
  50~59 2,001 (22.4) 401 (22.3)
  60~69 3,026 (33.9) 609 (33.8)
  70~79 1,637 (18.3) 332 (18.4)
  ≥ 80 425 (4.8) 89 (4.9)
 Sex 0.804
  Male 4,015 (45.0) 804 (44.6)
  Female 4,915 (55.0) 997 (55.4)
 Residence 0.963
  Seoul (metropolitan) 1,846 (20.7) 372 (20.7)
  2nd area 1,588 (17.8) 329 (18.3)
  3rd area 1,992 (22.3) 402 (22.3)
  4th area 3,504 (39.2) 698 (38.8)
 Household income 0.915
  0~30% 2,062 (23.1) 409 (22.7)
  30–70% 2,952 (33.1) 603 (33.5)
  70–100% 3,916 (43.9) 789 (43.8)
Table 1.  Characteristics of the study population (comparison group [n = 8,930] and retinal vein occlusion 
[RVO] group [n = 1,801]). Seoul, a metropolitan area in Korea; 2nd area included the largest province; 3rd area 
included the 2nd largest city and the 2nd and 3rd largest provinces; 4th area included other areas.
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Factors associated with AF occurrence. In multivariable model, we found that RVO was associated with a 
subsequent diagnosis of AF (hazard ratio [HR], 1.35; 95% confidence interval [CI], 1.09–1.67). HF (HR, 3.26; 95% 
CI, 2.65–4.02), hyperthyroidism (HR, 1.87; 95% CI, 1.09–3.19), acute myocardial infarction (HR, 1.55; 95% CI, 
1.00–2.41), cerebrovascular disease (HR, 1.30; 95% CI, 1.03–1.64), and liver disease (HR, 1.24; 95% CI, 1.01–1.54) 
were associated with AF development in our multivariable model (Table 2); however, other comorbidities were 
not associated with AF development. Compared to male sex, female sex was more strongly associated with a 
decreased risk of AF occurrence (HR, 0.70; 95% CI, 0.58–0.84).
RVO was associated with a higher incidence of AF in both men and women (men: HR, 1.65; 95% CI, 1.22–2.24 
vs. women: HR, 1.14; 95% CI, 0.85–1.54, Table 3). However, the HR was greater in men than in women, and in 
women, the result was not statistically significant. HF was the strongest predictive factor in both men and women 
(men: HR, 3.51; 95% CI, 2.58–4.78 vs. women: HR, 3.00; 95% CI, 2.26–3.98). In men, patients with hyperthy-
roidism (HR, 2.37; 95% CI, 0.96–5.86) and acute myocardial infarction (HR, 1.73; 95% CI, 0.94–3.16) were more 
likely to have an episode of AF, albeit marginally. In women, patients with cerebrovascular disease were more 
likely to have an episode of AF (HR, 1.37; 95% CI, 1.01–1.87).
The follow-up period of 79,482 person-years, including 66,244 person-years for the comparison group and 
13,238 person-years for the RVO group, was analyzed (Fig. 1). AF occurred in 8.8 per 1,000 person-years in the 
RVO group, and in 5.3 per 1,000 person-years in the comparison group. The incidence and risk of AF according to 
the presence of RVO were examined in each age and sex subgroups, and in the subgroups with or without comor-
bidities using multivariable Cox regression analysis. In the age subgroup analysis, subjects with RVO had a greater 
risk of subsequent AF in both age groups, albeit marginally in the older age group (age group < 65 years: HR, 
1.49; 95% CI, 1.06–2.12 vs. age group ≥ 65 years: HR, 1.27; 95% CI, 0.97–1.67). In men, RVO increased the risk of 
subsequent AF by an HR of 1.65 (95% CI, 1.22–2.24), whereas in women, the increased risk did not reach statis-
tical significance (HR, 1.14; 95% CI, 0.85–1.54). RVO had an independent predictive value for AF development 
Variables
Multivariable cox
adjusted HR 95% CI p-value
Group
 Comparison group 1 (ref)
 RVO group 1.35 1.09–1.67 0.006
Comorbidities (reference group: subjects without each comorbidity)
 Heart failure 3.26 2.65–4.02 < 0.001
 Hyperthyroidism 1.87 1.09–3.19 0.022
 Acute Myocardial Infarction 1.55 1.00–2.41 0.049
 Cerebrovascular disease 1.30 1.03–1.64 0.027
 Hypertension 1.19 0.95–1.49 0.121
 Diabetes mellitus 1.13 0.92–1.38 0.247
 Chronic kidney disease 1.03 0.71–1.48 0.876
 Chronic lung disease 1.17 0.97–1.41 0.102
 Liver disease 1.24 1.01–1.54 0.044
Age group (year)
 < 50 1 (ref)
 50~59 2.56 1.49–4.39 0.001
 60~69 3.56 2.13–5.97 < 0.001
 70~79 6.65 3.94–11.24 < 0.001
 ≥ 80 7.05 3.86–12.89 < 0.001
Sex
 Male 1 (ref)
 Female 0.70 0.58–0.84 < 0.001
Residence
 Seoul (metropolitan) 1 (ref)
 2nd area 1.14 0.86–1.52 0.362
 3rd area 0.94 0.71–1.25 0.681
 4th area 1.01 0.79–1.30 0.911
Household income
 0~30% 1 (ref)
 30–70% 1.07 0.83–1.38 0.602
 70–100% 0.97 0.76–1.22 0.773
Table 2.  Results of the multivariable Cox regression analysis for the overall incidence of atrial fibrillation 
(n = 10,731). CI, confidence interval; RVO, retinal vein occlusion; HR, hazard ratio. Seoul, a metropolitan area 
in Korea; 2nd area included the largest province; 3rd area included the 2nd largest city and the 2nd and 3rd 
largest provinces; 4th area included other areas.
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among subjects with HF (HR, 1.36; 95% CI, 1.05–1.76). However, in subjects without HF, the AF occurrence rate 
was relatively low (comparison group: 2.6 vs. RVO group: 3.8 per 1,000 person-years); thus, the difference was 
not statistically significant considering the large CI. In addition, in subjects with and without hypertension, DM, 
or chronic lung disease, RVO also increased the AF risk with HRs of > 1; however, in the subgroups of subjects 
without hypertension or DM but with chronic lung disease, the results did not reach statistical significance due 
to the wide CIs.
Variables
Men (n = 4,819) Women (n = 5,912)
adjusted HR (95% CI) p-value adjusted HR (95% CI) p-value
Group
 Comparison group 1(ref) 1(ref)
 RVO group 1.65 1.22–2.24 0.001 1.14 0.85–1.54 0.388
Comorbidities (reference group: subjects without each comorbidity)
 Heart failure 3.51 2.58–4.78 < 0.001 3.00 2.26–3.98 < 0.001
 Hyperthyroidism 2.37 0.96–5.86 0.062 1.69 0.87–3.31 0.123
 Acute Myocardial Infarction 1.73 0.94–3.16 0.077 1.50 0.78–2.87 0.224
 Cerebrovascular disease 1.19 0.83–1.69 0.344 1.37 1.01–1.87 0.044
 Hypertension 1.18 0.85–1.63 0.322 1.21 0.89–1.64 0.228
 Diabetes mellitus 1.12 0.82–1.52 0.474 1.12 0.85–1.47 0.420
 Chronic kidney disease 0.91 0.54–1.52 0.721 1.15 0.68–1.94 0.600
 Chronic lung disease 1.14 0.86–1.51 0.370 1.20 0.93–1.55 0.152
 Liver disease 1.16 0.86–1.58 0.330 1.32 0.98–1.77 0.068
Table 3.  Results of multivariable Cox regression analysis after adjusting for sociodemographic factors 
for the overall incidence of atrial fibrillation according to sex. CI, confidence interval; RVO, retinal vein 
occlusion; HR, hazard ratio.
Figure 1. Incidence and risk of atrial fibrillation (AF) in the retinal vein occlusion (RVO) and comparison 
groups. Incidence rate per 1,000 person-years. CI, confidence interval; HR, hazard ratio. HRs were calculated 
based on multivariable Cox regression after being adjusted for sociodemographic factors and comorbidities. 
The P for interaction was calculated using the interaction term for RVO and each subgroup based on the 
multivariable Cox regression.
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Survival curves for AF. Figure 2 displays the Kaplan-Meier survival curves for up to 11 years. Overall, com-
pared to patients in the comparison group, those with RVO experienced AF more frequently (Fig. 2A). The 
AF-free survival rates were different between the two groups regardless of the age subgroup (Fig. 2B). In terms 
of sex, the AF-free survival rate decreased faster starting early in the study period in men with RVO compared to 
men without RVO; this trend was not found in women (Fig. 2C).
Discussion
We found an temporal relationship between newly developed RVO and subsequent AF development.
Recently, the retinal vasculature has gained more attention, because it is unique in that the retinal artery or 
vein and abnormal vasculature such as hypertensive retinopathy can be directly visualized using ophthalmos-
copy. Therefore, RVO could be a surrogate marker for cardiovascular disease such as hypertension or stroke12. 
Although a new onset of RVO mainly causes decreasing vision, peripheral RVO does not affect vision in some 
cases. Therefore, the patient may not know about an RVO occurrence in his or her eyes. Underdiagnosed RVO 
could be detected by an ophthalmologist through the diagnosis of an eye complication such as sclerotic vessel 
change, optociliary shunt vessels (collaterals), sequelae of neovascularization, or thinning of the retinal nerve 
fiber layer17–20. The evaluation of these signs based on a retinal examination in vivo could be an easy, non-invasive 
way to stratify the risk of cardiovascular/cerebrovascular disease.
The characteristics of RVO are similar to those of stroke, because the structure of the retina is derived from 
the central nervous system21. Our previous study showed that RVO significantly increases the risk of stroke, with 
an HR of 1.48 (95% CI, 1.24–1.76) after adjusting for comorbidities12. AF has been the most common risk factor 
associated with stoke22. One case-control study showed that AF was more common in a CRVO group; however, 
cases of AF were excluded from the final model of stepwise logistic regression analysis23. According to a nation-
wide cohort study in Denmark of 605 patients with RVO retinal vascular (artery or vein) occlusion among 86,572 
patients with non-valvular AF, RVO significantly increased the risk of stroke among patients with AF (HR, 1.26; 
95% CI, 1.02–1.54)24. In this study, retinal vein or artery occlusion was suggested to be an independent risk factor 
for stroke in AF; therefore, it would merit at least 1 or 2 points in the CHA2DS2-VASc scoring system, fulfilling 
the stroke/thromboembolism criterion or vascular criterion24. In our study, RVO increased the likelihood of AF. 
Finally, RVO alone was independently associated with an increased risk of stroke and AF, and RVO increased the 
stroke risk in patients with AF. However, the effect size of the HRs could not be compared directly between studies 
because of the different ethnic populations and study designs.
The present study showed that the overall AF development was more common in men (Table 2), which is 
consistent with the results of previous reports25–27. Nevertheless, HF is one of the strongest predictors for incident 
AF in men (HR, 3.51) and women (HR, 3.00). However, other risk factors showed sex-related differences in terms 
of the AF risk. In a previous population-based study using a Danish cohort, hyperthyroidism was more common 
in women. However, male sex was associated with AF in those with hyperthyroidism28, and this significant result 
was consistent with our results. In a previous study using the Canadian Registry of AF, myocardial infarction 
was more prevalent in men, whereas stroke was more prevalent in women at the time of the initial presentation 
of AF29. In the present study, the HR for AF due to acute myocardial infarction was also greater in men than in 
women, and the HR for AF due to cerebrovascular disease was greater in women than in men. Results of previous 
studies and our study all indicate that there are sex-related differences in the clinical burden of AF. In particular, 
RVO also showed a sex-dependent association: RVO significantly increased the incidence AF in men, not in 
women (Table 3). Figure 2C also shows the different trends in the AF risk between men and women over time. 
The relatively large gap in the AF incidence between the two groups in men was sustained from the beginning to 
the end of the study period. However, the gap was relatively small in women. In our previous studies, RVO was a 
stronger predictor for acute myocardial infarction in younger men rather than in younger women14. In addition, 
RVO was a stronger predictor of HF in men than in women13. Sex-related differences have been recognized thus 
far, and RVO could be a possible cause of AF, acute myocardial infarction14, and HF13, particularly in men, as well 
as a cause of stroke in men and women12.
Figure 2. Kaplan-Meier survival curves for atrial fibrillation (AF) development in the retinal vein 
occlusion (RVO) and comparison groups during the study period. The cumulative AF-free survival curve  
(A) and AF-free survival curves grouped by age (B) and sex (C).
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In accordance with previously published reports, we found that HF30, hyperthyroidism28, acute myocardial 
infarction, cerebrovascular disease, and liver disease31 were predictors of incident AF32. However, other comor-
bidities such as hypertension, DM, CKD, and chronic lung disease were not associated with AF based on our 
multivariable model. In the stratified analysis by HF (Fig. 1), RVO increased the risk of AF with an HR of approx-
imately 1.3 in both subjects with or without HF. These results suggest an independent predictive value for RVO as 
well as HF for AF. Of note, RVO could be a better and earlier stage predictor for AF compared to other cardiovas-
cular risk factors including hypertension, DM, or CKD.
Retinal microcirculation can be assessed non-invasively, directly, and safely. Retinopathy has been assumed to 
be a surrogate marker for microvascular dysfunction, which plays a pivotal role in the development of metabolic 
syndrome and cardiovascular disease33–35. Recently, metabolic syndrome has been assumed to be an important 
risk factor for AF development36,37. Autonomic neuropathy, oxidative stress, myocardial fibrosis, and microvascu-
lar dysfunction could be the underlying pathophysiologic mechanism for this association38,39. Further research to 
determine the causality and underlying mechanisms associated with the occurrence of AF and RVO is warranted. 
This epidemiological study does not provide evidence for the mechanism of RVO and AF.
The strengths of the present study include the large number of subjects and a long-term follow-up. Previous 
studies have shown an association between RVO and other cardio/cerebrovascular diseases such as stroke, hyper-
tension, and DM. However, there have been no previous reports about the association between RVO and AF. This 
is the first report to examine AF development following RVO.
The most major limitation of the present study was the potential inaccuracy of the KCD code-diagnoses of 
RVO and AF. The accuracy of the health insurance service claims regarding RVO were mentioned in our previous 
report based on the NHIS-NSC 2002–2009 database12. The use of medical insurance claims dataset and the accu-
racy of these dataset are relevant issues to consider in the clinical setting. Unfortunately, there were no previous 
studies about the validity of national insurance claims for AF in South Korea. However, in Fig. 2A, the incidence 
of AF in the comparison group consistently increased for 11 years; this may partially represent the validity of AF 
diagnosis in our study. In addition, due to their asymptomatic nature, nasal occlusions are less likely to be diag-
nosed and reported. However, if patients with nasal-side RVO belong to the comparison cohort, the real HR may 
be greater than the current HR, as RVO increased the risk of AF.
Aside from the aforementioned possible inaccuracy of the KCD code-based diagnosis of RVO and AF, the 
following limitations of this study should be mentioned: (1) the possible misclassification of diagnoses for RVO, 
AF, or comorbidities; (2) possible underreporting of asymptomatic RVO or paroxysmal AF; (3) possibility of the 
delayed diagnosis of RVO or AF due to delayed visits to physicians; (4) possibility of inappropriately included 
patients with chronic RVO or AF; (5) potential that other health behavioral information such as alcohol use 
is missing; (6) higher possibility of bias among control patients from the medical claims than among control 
patients from the general population who have not received medical care; and (7) possible ethnic differences that 
may exist in ethnic groups other than the South Korean population that were not considered in this study.
In summary, RVO was associated with subsequent AF development in our multivariable Cox model. A retinal 
examination may be a safe method to evaluate one’s risk of AF. Therefore, ophthalmologists and cardiologists 
should be cautious of patients with RVO, as these patients, especially in men, should undergo cardiovascular 
risk screening to check for these disorders. These findings are limited, and they need to be confirmed by other 
observational studies.
Methods
Ethic statement. The institutional review board (IRB) of Severance Hospital at Yonsei University College 
of Medicine in Seoul, Korea approved this retrospective cohort study. The IRB waived the requirement to obtain 
informed consent, and this study was conducted in accordance with the tenets of the Declaration of Helsinki.
Data source. This retrospective cohort study used the NHIS-NSC 2002–2013 dataset, comprising a random 
sample of 1,025,340 subjects, which amounted to approximately 2.2% of the entire population in the Korean 
NHIS in 2002. Data were produced by the NHIS using a systematic sampling method for the purpose of research. 
Random sampling was used based on 1,476 strata. As all individuals in South Korea are enrolled in the NHIS, 
All available data in the NHIS are centralized and include complete information, including diagnostic codes, 
procedures, prescription drugs used, and personal information for inpatient and outpatient visits. Moreover, 
diagnostic codes based on the KCD have been used in South Korea, and they are comparable to the International 
Classification of Diseases (ICD).
Study population. The inclusion criteria were as follows: (1) patients in the study cohort who received 
medical care between 1st January 2003 and 31th December 2007 with a newly diagnosed RVO (KCD code H34.8, 
corresponding to ICD-9-CM codes 362.35, CRVO or 362.36, venous tributary [branch] occlusion); (2) subjects 
(comparison cohort) extracted using propensity-score matching (5 per each patient with RVO) from the database 
of 1 million subjects without RVO between January 2003 and December 2007; and (3) patients newly diagnosed 
as having AF (KCD code I48, corresponding to ICD-9-CM code 427.3, AF and flutter) from 2003–2013 to assess 
the outcome variable, AF occurrence. The exclusion criteria were as follows: (1) patients with chronic RVO before 
2003; (2) patients with chronic AF before 2003; and (3) patients with AF occurrence before the occurrence of 
RVO, based on the patient’s visit date.
The variables for matching were as follows: (1) age (< 50/50–59/60–69/70–79/≥ 80 years), (2) sex, (3) res-
idential area, (4) household income (≤ 30%, 30–70%, and ≥ 70% of the median), and (5) year of enrollment 
(2003–2007). Comorbidities such as HF, hyperthyroidism, acute myocardial infarction, cerebrovascular disease, 
hypertension, DM, CKD, chronic lung disease, and liver disease were diagnosed based on the KCD, and they were 
defined as any diagnoses made from 2002–2007 (Supplementary Table 1).
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Statistical analysis. Characteristics of the study population were presented with descriptive statistics. 
We matched the RVO and comparison groups based on propensity score matching; the propensity scores were 
estimated by logistic regression analysis to predict RVO occurrence, and we controlled for age, sex, residency, 
income, and year of enrollment. Matching was performed using the greedy 8→ 1 digit-matching macro with a 
propensity score. Once a match was made, the match was not considered again. From the preliminary analysis 
based on the formula by Schoenfeld40, we could achieve more than 80% power with a sample size of 10,000 
(ratio of cases to controls, 1:5) and an AF incidence of 4% for detecting an HR of 1.32 or greater. Each patient 
was tracked for up to 11 years from the first visitation date with a diagnosis of RVO (RVO group) or a randomly 
selected visitation date in the matched year (control group) to the last follow-up date in 2013 or to the date of 
the first diagnosis of AF. The overall AF survival rate was described using a Kaplan-Meier survival curve from 
2003–2013 (median, 7.7 years). An association between RVO and the prospective risk of AF development was 
evaluated using Cox proportional hazard model. HRs with 95% CIs were calculated using a multivariable model. 
For subgroup analyses, the groups were stratified according to age, sex, and the presence of comorbidities. As the 
proportions of heart failure (26.0%), hypertension (42.7%), DM (20.7%), and chronic lung disease (30.1%) were 
relatively high (> 20%) in the entire cohort, these comorbidities were used for subgroup analyses; the groups 
were stratified into patients with heart failure, hypertension, DM, or chronic lung disease and those without 
these comorbidities. A significance level of α 5% was considered statistically significant. Stata/MP2, version 14.0 
(StataCorp, College Station, TX, USA) and the SAS System for Windows, version 9.4 (SAS Institute Inc., Cary, 
NC, USA) were used to perform the analyses.
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